SCHEDULE: Fairmount Funds Reduces Cogent Biosciences Stake to 8.6%

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC reported a significant reduction in their beneficial ownership of Cogent Biosciences, Inc. common stock following a conversion and block sale.

Summary

• Fairmount Healthcare Fund II L.P. converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock on March 31, 2026, for no cash consideration.
• Immediately following the conversion, Fund II sold all 7,000,000 newly converted Common Stock shares in a block trade at a price of $34.66 per share.
• After these transactions, the reporting persons beneficially own an aggregate of 15,356,918 shares of Cogent Biosciences, Inc. Common Stock.
• This aggregate ownership represents 8.6% of the company's outstanding Common Stock as of March 31, 2026.
• The remaining beneficial ownership consists of 5,503,418 shares of Common Stock and 9,853,500 shares of Common Stock issuable upon conversion of 39,414 shares of Series A Preferred Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative event due to the significant reduction in a major institutional investor's stake, which could signal reduced confidence or create selling pressure.

Negatives

• A significant institutional investor, Fairmount Healthcare Fund II L.P., reduced its stake by selling 7,000,000 shares of Common Stock, which could be interpreted as a decrease in conviction or a portfolio rebalancing.
• The block sale of 7,000,000 shares at $34.66 per share could exert downward pressure on the stock price in the short term due to increased supply.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that significant block sales by institutional investors in the biotechnology sector can sometimes signal a shift in investment strategy or a re-evaluation of a company's near-term prospects, even if the underlying company fundamentals remain strong. Such sales can create short-term volatility for the stock.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional investors frequently rebalance portfolios, and a reduction from a higher percentage to 8.6% is not uncommon. For example, similar divestments have been seen with other healthcare-focused funds like Orbimed or RA Capital Management in their portfolio companies, often driven by fund-specific liquidity needs or strategic shifts rather than solely company performance.

Stakeholder Impact

• Shareholders: The sale of a large block of shares could lead to increased supply and potential downward pressure on the stock price, impacting existing shareholders.
• Company: The reduction in a significant institutional stake might be viewed negatively by other potential investors, affecting future capital-raising efforts or market perception.

Key Dates

Recommendation

While a significant institutional investor has reduced its stake, this Schedule 13D amendment primarily reports a change in beneficial ownership and does not provide new information on the company's operational performance or strategic direction. The sale could be due to portfolio rebalancing rather than a fundamental change in the company's prospects. Investors should hold and monitor future company announcements and market reactions for a clearer picture.

Keywords

Cogent Biosciences, Fairmount Funds Management, Fairmount Healthcare Fund II, Schedule 13D, Beneficial Ownership, Stock Sale, Preferred Stock Conversion, Block Trade, Biotechnology, Healthcare Investment